The ATM facility creates persistent overhang — the company can sell shares into the market at any time, likely to fund the extended roluperidone trial. Monitor daily volume and price action for signs of ATM execution. The 12-week extension of the relapse phase pushes a key catalyst (relapse data) to H2 2028, extending the cash-burn timeline and increasing the probability of further dilution.
Price Chart
Executive Summary
Minerva Neurosciences entered into an at-the-market (ATM) equity offering agreement with Leerink Partners to sell up to $75 million of common stock, filed concurrently with a prospectus supplement for the same amount. Separately, the company disclosed a revision to its Phase 3 roluperidone trial, extending the relapse assessment phase from 40 to 52 weeks following FDA feedback, with topline efficacy results still expected in H2 2027 and relapse data in H2 2028. The ATM facility, filed just 9 days after a 424B5 for the same $75M program, signals potential near-term dilution to fund ongoing clinical development.
Key Facts
- Entered into an ATM sales agreement with Leerink Partners to sell up to $75 million of common stock.
- The ATM offering is under an existing S-3 shelf registration (File No. 333-294203) effective March 19, 2026.
- Agent commission is 3.0% of gross proceeds from any sales.
- Phase 3 C19 trial for roluperidone (negative symptoms of schizophrenia) relapse assessment phase extended from 40 to 52 weeks after FDA feedback.
- Topline efficacy results still expected in H2 2027; relapse assessment data expected in H2 2028.
- The 424B5 prospectus supplement for the same $75M ATM was filed 9 days prior (May 27, 2026), confirming the capital raise is financing the clinical program.
Financial Impact
Up to $75 million in potential dilution at the company's discretion via ATM sales; no specific shares or prices disclosed.
Risk Factors
- ATM sales could accelerate, causing significant dilution if the stock price weakens.
- Phase 3 roluperidone trial may fail or be delayed further, rendering the ATM proceeds a sunk cost.
- Extended trial timeline (relapse data in H2 2028) increases cash needs beyond the $75M ATM capacity.
- No revenue or near-term catalysts to offset dilution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-241930 |
| Document: d119518d8k.htm | 0001193125-26-241930 |
| Document: d119518dex51.htm | 0001193125-26-241930 |
| Document: 0001193125-26-241930-index-headers.html | 0001193125-26-241930 |
| Document: 0001193125-26-241930-index.html | 0001193125-26-241930 |
| Document: 0001193125-26-241930.txt | 0001193125-26-241930 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | 8-K | $3.92 | awaiting T+60 | — | $2.20 (−43.88%) |
Aug 7, 2026 11w ago | 8-K | $4.27 | awaiting T+60 | — | $2.20 (−48.48%) |
May 27, 2026 21w ago | 8-K | $5.00 $4.84 | ▲ +3.20% | ▲ +4.93% | $2.20 (+56.00%) |
May 5, 2026 24w ago | 8-K | $6.25 $4.02 | ▼ −35.68% | ▼ −38.42% | $2.20 (−64.80%) |
Apr 23, 2026 26w ago | DEFA14A | $6.83 $4.37 | ▼ −36.02% | ▼ −41.04% | $2.20 (−67.79%) |
Mar 25, 2026 30w ago | Press Release | $6.14 $4.66 | ▼ −24.10% | ▼ −38.05% | $2.20 (−64.17%) |
Mar 20, 2026 31w ago | EFFECT | $7.54 $4.39 | ▼ −41.78% | ▼ −56.20% | $2.20 (−70.82%) |
Mar 11, 2026 32w ago | S-3 | $7.30 $4.68 | ▲ +35.89% | ▲ +47.41% | $2.20 (+69.86%) |
Mar 11, 2026 32w ago | Press Release | $7.30 $4.68 | ▼ −35.89% | ▼ −47.41% | $2.20 (−69.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers